Pursuant to Regulations 30, 33 and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gujarat Inject Kerala Ltd reported strong audited standalone results for FY2025-26. Revenue from operations grew 91% to ₹3,632.04 Lakhs from ₹1,904.58 Lakhs in the previous year. Profit after tax surged 78% to ₹181.41 Lakhs from ₹101.72 Lakhs, while EPS improved to ₹1.24 from ₹0.70. The company generated positive operating cash flow of ₹2,122.01 Lakhs compared to negative ₹352.20 Lakhs in the prior year. Statutory auditors M/s S. Mandawat & Co. issued an unmodified (clean) audit opinion on the financial statements. The Board meeting was held on May 20, 2026.
The company demonstrated exceptional revenue and profit growth with significant improvement in cash generation, signaling strong operational performance. Shareholders may view this positively given the clean audit opinion and turnaround in cash flows.